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Introduction 
Cowden syndrome (CS) is a rare genetic condition 
that belongs to a spectrum of diseases derived from 
phosphatase and tensin homolog (PTEN) gene 
mutations, which compose the PTEN hamartoma 
tumor syndrome (PHTS), [1]. Clinical presentation 
includes multiple benign lesions and several 
malignant neoplasms [1, 2]. Mucocutaneous lesions 
usually appear within the first couple of decades, 
allowing dermatologists to suspect this condition 
before malignant neoplasms develop [3]. 
The diagnosis is classically based on clinical criteria, 
periodically updated by the National Comprehensive 
Cancer Network (NCCN), [2], though confirmatory 
genetic testing is frequently used. Other criteria may 
serve as tools for selecting patients for genetic 
testing, such as the NCCN's PTEN testing criteria 2 
and the Cleveland Clinic clinical scoring system for 
phenotype-based pre-test probability [4]. Multiple 
PTEN gene mutations have been identified, though 
the different types apparently do not indicate clinical 
variability [5]. 
 
Case Synopsis 
A 52-year-old woman consulted for multiple warts of 
her hands and feet. She had been treated repeatedly 
with topical agents and cryotherapy. Her medical 
history included thyroidectomy for multinodular 
goiter, bilateral cholesteatoma, hysterectomy for 
uterine fibroids, trigeminal schwannoma, tracheal 
fibrotic nodules, and a finger fibroma. There was no 
family history of multiple neoplasms or hereditary 
syndromes. 
Physical examination revealed keratotic, wart-like 
papules on the dorsum of hands and feet, and round, 
keratotic palmoplantar pits (Figure 1). Centrofacial 
and periorificial keratotic papules of 1-2 millimeters 
were also identified (Figure 1). Oral examination 
revealed a buccal polypoid papule and gingival 
papillomatosis (Figure 2). Head circumference was 
below the 97th percentile. 
Abstract 
Cowden syndrome (CS) is an infrequent 
genodermatosis caused by mutations in the 
phosphatase and tensin homolog (PTEN) gene in the 
majority of cases. As such, it belongs to the PTEN 
hamartoma tumor syndrome spectrum. This disease 
has a variable clinical expression characterized by the 
development of multiple hamartomatous tumors in 
different organs, usually during the second and third 
decades of life, and a high cumulative risk of several 
malignancies. We present a case of Cowden 
syndrome with late diagnosis presenting with a florid 
dermatological expression and multiple benign 
tumors, but no malignancies. A novel PTEN mutation 
was identified. 
Volume 25 Number 5| May 2019| 
25(5): 14 
 
 
- 2 - 
Dermatology Online Journal  ||  Photo Vignette
The histopathology of acral and facial papules was 
consistent with trichilemmoma. Gingival biopsy 
showed verrucous hyperplasia with no dysplasia. 
The buccal lesion was an oral fibroma. Breast cancer 
screening was negative. Gastrointestinal endoscopy 
revealed glycogenic acanthosis and ten colorectal 
inflammatory and hyperplastic polyps. 
She met sufficient NCCN genetic testing criteria and 
scored 77% (52.7-91.3%) in the Cleveland Clinic 
scoring system. PTEN gene study revealed a 
heterozygous mutation: a four-nucleotide deletion 
(c.510_513del) resulting in a premature stop codon 
(p.Ser170Argfs*12). No reference of this mutation 
was found in published literature and genetic 
databases. 
 
Case Discussion 
We present a ‘de novo’ case of CS, with late diagnosis 
and atypical presentation, in which a novel PTEN 
mutation was identified. 
Although our patient was diagnosed with CS at 52 
years of age, the diagnosis is usually made earlier 
based on familial history and mucocutaneous 
findings, since the latter develop during the first 
decades of life [3]. Early diagnosis is important for 
correct management of the risk of malignancies, 
which typically develop before the sixth decade of 
life [2, 3]. Our patient has reached this age and 
fortunately remains malignancy-free. 
The diagnosis of CS relies heavily on its clinical 
diagnostic criteria. According to the latest updates in 
the NCCN guidelines these include breast, 
endometrial (epithelial), and thyroid (follicular) 
cancer. Additional associations include ≥3 
gastrointestinal hamartomas (including 
ganglioneuromas, but excluding hyperplastic 
polyps), Lhermitte-Duclos disease (dysplastic 
gangliocytoma of the cerebellum), macrocephaly 
(≥97th percentile), macular pigmentation of the glans 
penis, and mucocutaneous lesions as major criteria. 
The latter is fulfilled when presenting any of the 
following: ≥3 trichilemmomas (at least one biopsy 
proven), ≥3 acral keratoses (palmoplantar keratotic 
pits and/or acral hyperkeratotic papules), ≥3 
mucocutaneous neuromas, and/or ≥3 oral 
papillomas. Minor criteria include autism spectrum 
disorder, colon cancer, ≥3 esophageal glycogenic 
 
Figure 1. Cutaneous lesions. A) Round keratotic palmar pits. B) Millimetric keratotic papules with centrofacial and periorificial 
distribution. B 
A B
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acanthoses, ≥3 lipomas, intellectual disability, renal 
cell carcinoma, testicular lipomatosis, thyroid cancer 
(papillary or follicular variant of papillary), thyroid 
structural lesions (including adenoma and 
multinodular goiter), and vascular anomalies. 
Among individuals without a family history of 
CS/PHTS, clinical diagnosis can be made when 
meeting ≥3 major criteria or by meeting two major 
and three minor criteria. Our patient only met one 
major criterion (mucocutaneous lesions) and two 
minor criteria (glycogenic acanthosis and thyroid 
structural lesions). Therefore, despite presenting 
with multiple mucocutaneous lesions and a high 
clinical suspicion from a dermatological perspective, 
she did not meet sufficient NCCN criteria for the 
operational clinical diagnosis [2]. However, the NCCN 
criteria for PTEN testing [2] includes these items but 
requirements are less rigorous. The CC Cleveland 
Clinic system [5] also takes into account a wider 
range of manifestations. The latter two are useful 
tools supporting genetic testing. 
Study of the PTEN gene identified a novel mutation 
that was considered pathological owing to the 
presumed deleterious effect on the PTEN protein. It 
is unclear whether this particular mutation is related 
to our patient's clinical features and non-malignant 
course. 
 
Conclusion 
This case underlines the importance of 
dermatological evaluation in the diagnosis of 
CS/PHTS and the usefulness of developing testing 
criteria, which take into account this spectrum's 
significant clinical variability. This highlights the 
need for continued revision of clinical diagnostic 
criteria and study of possible mutation-phenotype 
associations. 
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Figure 2. Oral lesions. A) Polypoid lesion on the buccal mucosa. B) Gingival papillomatosis. 
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